Impact of Cardiac Implantable Electronic Device Infection
暂无分享,去创建一个
J. Healey | G. Boriani | B. Wilkoff | Sarah Willey | R. Augostini | K. Tarakji | S. Mittal | C. Kennergren | G. Corey | J. Poole | R. Holbrook | S. Faerestrand | J. Love | D. Lexcen | J. Lande | R. Corey | Sherman S Wiggins
[1] B. Wilkoff,et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection , 2019, The New England journal of medicine.
[2] S. Connolly,et al. Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. , 2018, Journal of the American College of Cardiology.
[3] A. Greenspon,et al. Treatment patterns, costs, and mortality among Medicare beneficiaries with CIED infection , 2018, Pacing and clinical electrophysiology : PACE.
[4] E. Fenwick,et al. Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection , 2018, Journal of medical economics.
[5] M. Shoda,et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. , 2017, Heart rhythm.
[6] B. Wilkoff,et al. Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT). , 2016, American heart journal.
[7] A. Greenspon,et al. Incidence, Treatment Intensity, and Incremental Annual Expenditures for Patients Experiencing a Cardiac Implantable Electronic Device Infection: Evidence From a Large US Payer Database 1-Year Post Implantation , 2016, Circulation. Arrhythmia and electrophysiology.
[8] Christopher R. Ellis,et al. Cardiac Implantable Electronic Device Infection in Patients at Risk. , 2015, Arrhythmia & electrophysiology review.
[9] S. Saba,et al. Health and Economic Outcomes Associated with Use of an Antimicrobial Envelope as a Standard of Care for Cardiac Implantable Electronic Device Implantation , 2015, Journal of cardiovascular electrophysiology.
[10] C. Henrikson,et al. Increased Long‐Term Mortality in Patients with Cardiovascular Implantable Electronic Device Infections , 2015, Pacing and clinical electrophysiology : PACE.
[11] Walid Saliba,et al. Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[12] J. Curtis,et al. Rates of and Factors Associated With Infection in 200 909 Medicare Implantable Cardioverter-Defibrillator Implants: Results From the National Cardiovascular Data Registry , 2014, Circulation.
[13] C. Henrikson,et al. Mortality and cost associated with cardiovascular implantable electronic device infections. , 2011, Archives of internal medicine.
[14] Daniel R. Frisch,et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. , 2011, Journal of the American College of Cardiology.
[15] H. Mond,et al. The 11th World Survey of Cardiac Pacing and Implantable Cardioverter‐Defibrillators: Calendar Year 2009–A World Society of Arrhythmia's Project , 2011, Pacing and clinical electrophysiology : PACE.
[16] M. Porter,et al. What is value in health care? , 2010, The New England journal of medicine.
[17] B. Wilkoff,et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes. , 2010, Heart rhythm.
[18] Jeffrey A. Johnson,et al. Using Instrument-Defined Health State Transitions to Estimate Minimally Important Differences for Four Preference-Based Health-Related Quality of Life Instruments , 2010, Medical care.
[19] Stephen Joel Coons,et al. US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.
[20] G W Torrance,et al. Utility approach to measuring health-related quality of life. , 1987, Journal of chronic diseases.